May 1st 2024
The FDA approved a high-concentration, citrate-free version of Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), making it the second high-concentration adalimumab biosimilar to have an interchangeability designation.
Vizient Report Predicts Over 3% Inflation Rate for Biologics
February 7th 2023Vizient’s Pharmacy Market Outlook report examined the impact that factors, such as the COVID-19 pandemic and the US market introduction of adalimumab biosimilars, will have on drug prices and the utilization of lower-cost biologics.
High Treatment Retention Following Biosimilar-to-Biosimilar Switch in Denmark
February 4th 2023A real-world study assessing the aftermath of Denmark implementing a nationwide mandatory switch from one infliximab to another found strong treatment retention rates, demonstrating the safety and tolerability of biosimilar-to-biosimilar switching.
Biosimilar Rheumatology Roundup: January 2023
February 1st 2023This year started off with a bang for rheumatology biosimilars, with several regulatory approvals around the world, new market insight into the global use of biosimilars, and US market introduction of the first rival biosimilar to Humira (adalimumab).
Eye on Pharma: New Partnerships; Samsung Adalimumab Updates; Phase 3 Ustekinumab Results
January 22nd 2023Alteogen and Alvotech announce updates for their respective license partnerships; Samsung Bioepis speeds up interchangeability study for its adalimumab biosimilar; Dong-A ST shares positive phase 3 results for its ustekinumab biosimilar.
Study: Does Adalimumab Lose Effectiveness After Switching to a Biosimilar?
January 7th 2023The authors of an retrospective real-world study of patients with hidradenitis suppurativa treated with adalimumab concluded that switching patients between adalimumab products risked a greater likelihood of loss of effectiveness.
FDA Accepts BLA for Alvotech Ustekinumab Biosimilar
January 6th 2023Alvotech, an Iceland-based company, announced that the FDA accepted its biologics license application (BLA) for its proposed ustekinumab biosimilar referencing Stelara. The company said it expects the FDA’s decision in the second half of 2023.
TNF Inhibitor Biosimilar Use in France
December 31st 2022A study assessing the use of tumor necrosis factor (TNF) alpha inhibitor biosimilars in France found that the biosimilar penetration rate was higher for infliximab compared to etanercept and adalimumab. The authors said they aimed to understand the key drivers for biosimilar use to improve biosimilar uptake in France.
Eye on Pharma: Janssen Sues Amgen, Express Scripts to Cover Adalimumab Biosimilar
December 19th 2022Janssen filed a lawsuit against Amgen, claiming the latter infringed on the former’s patents when creating its ustekinumab biosimilar, and Express Scripts announced that it would add adalimumab biosimilars to formulary.
Alvotech, STADA Launch Adalimumab Biosimilar in 7 More European Countries
December 8th 2022Following their initial European launch of the drug, Alvotech and STADA Arzneimittel launch their adalimumab biosimilar referencing Humira in 7 more European countries: Belgium, Bulgaria, Croatia, the Czech Republic, Latvia, Romania, and Slovenia.
AMCP Nexus Abstracts Investigate Adoption, Budget Impact of Biosimilars
November 8th 2022Abstracts presented at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting explored the adoption of infliximab biosimilars, utilization patterns of bevacizumab biosimilars in ophthalmology and oncology settings, and the budget impact of transferring patients to a natalizumab biosimilar from the originator.
A Summary of the VOLTAIRE-RA Trial for Physicians, Patients Considering RA Treatment Options
November 5th 2022Authors of a plain-language summary of the VOLTAIRE-RA study examined how to help patients with rheumatoid arthritis (RA), their families, patient advocates, and health care professionals learn about potential new treatment options as the United States prepares for the introduction of adalimumab biosimilars.
IQVIA: Semglee Experience Can Help Predict Adalimumab Biosimilar Adoption
November 3rd 2022A report from IQVIA recapped the US experience with Semglee, an insulin glargine biosimilar that has versions with and without an interchangeability designation, to help predict the adoption patterns of adalimumab biosimilars when they enter the market in 2023.
Cardinal Health Reports Increased Confidence in Biosimilars Among Rheumatologists
October 22nd 2022A report from Cardinal Health tells that rheumatologists are more familiar and confident in biosimilars compared with 2020, showing that education efforts are effective and that rheumatologists are more willing to prescribe biosimilars to their patients.
Rituximab Biosimilar Plus Methotrexate Improves Outcomes in Rheumatoid Arthritis
October 8th 2022A placebo-controlled clinical trial found that rituximab biosimilar HLX01 in combination with methotrexate was successful at improving the clinical outcomes of patients with moderate-to-severe rheumatoid arthritis.